Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isavuconazole versus caspofungin followed by voriconazole for candidemia and invasive Candida infections
2006-003951-18Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of isavuconazole in candidemia and invasive candidiasis (2 arms), sponsored by Astellas Pharma. Primary endpoint: Overall response at the end of IV therapy. Started Nov 2006; status: completed.
02
Drugs
isavuconazole
03
Conditions
candidemiainvasive candidiasis
Beyond the preview
Go deeper on 2006-003951-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003951-18.